How GPCR-targeting therapies are advancing the fight against inflammatory disease
Drug Target Review
JUNE 16, 2025
In this article, Stephan Schann, Chief Scientific Officer at Domain Therapeutics , explains why this class of drug target is so useful despite the challenges they present. GPCR-targeting therapies such as DT-9046 represent a compelling opportunity in that respect, with major clinical and commercial potential.
Let's personalize your content